clinical trial · NCT04050709
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Locally Advanced Solid TumorMetastatic CancerSolid TumorPD-L1 t-haNK
brief summary
Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with locally advanced or metastatic solid cancers.
started
Jul 18, 2019
primary completion
Mar 30, 2021
completion
Mar 25, 2026
last updated
Apr 1, 2026
detailed description
Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose for subjects with locally advanced or metastatic solid cancers. The study will be conducted in 2 parts: part 1 will involve dose escalation and part 2 will involve expansion of the recommended phase 2 dose.
official title
Open-Label Phase 1 Study of PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol